“Sleep medicines like Ambien are safe to take regularly.”
Sleep medicines like Ambien are not considered safe for routine long-term use; they are approved for short-term treatment and carry a boxed warning.
Prescription sleep pills like Ambien are meant for short-term use, not as a nightly habit for years. If you take one regularly, keep taking it as prescribed and ask your prescriber to review whether it still helps and whether CBT-I could take its place.
At your next visit, go over the exact drug, dose, how long you have taken it, any next-day effects, alcohol and other sedating medicines with your prescriber, and ask about CBT-I.
Safety note: Zolpidem, eszopiclone and zaleplon can cause sleepwalking, sleep driving and other activities while not fully awake, which have led to serious injuries and deaths; stop the medicine and call your prescriber if this happens. Do not combine them with alcohol, opioids or other sedating medicines, and do not drive the next morning if you may still be impaired, since impairment can happen even when you feel awake. Stopping suddenly after regular use can cause withdrawal, so change or stop the dose only with your prescriber.
Talk to a healthcare professional if: you have had a fall, confusion, memory gaps or a sleep behavior you do not remember, you feel you need a higher dose, you are pregnant or have breathing problems, or your insomnia continues; get urgent help for sleep driving, severe breathing trouble or an overdose.
The FDA label for zolpidem approves it for short-term use and carries a boxed warning for dangerous sleep behaviors, and major guidelines recommend CBT-I first, with sleep medicines as a short-term option. Confidence is moderate because long-term studies are limited and the risks differ between medicines and between people.
Sleep medicines like Ambien are not considered safe for routine long-term use; they are approved for short-term treatment and carry a boxed warning. Risks named on the label include sleepwalking and sleep driving, next-day impairment even when you feel awake, falls, and dependence that grows with dose and length of use. The grain of truth is that the most serious problems, like sleep driving, are rare, and some people do use them longer under a prescriber's regular review.
The label for extended-release zolpidem says treatment should be as short as possible and that longer use should not happen without a review, because the risk of dependence grows with time. The American College of Physicians recommends CBT-I as the first treatment for chronic insomnia, with medicine as a short-term option chosen together with the patient if CBT-I alone has not worked. The American Academy of Sleep Medicine gives only weak recommendations for individual sleep medicines, including zolpidem.
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125-133. DOI: 10.7326/M15-2175. PMID: 27136449
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. 2017;13(2):307-349. DOI: 10.5664/jcsm.6470. PMID: 27998379. PMCID: PMC5263087
- US Food and Drug Administration / Cosette Pharmaceuticals. AMBIEN CR (zolpidem tartrate extended-release) prescribing information. Label effective 2025-02-07. DailyMed set ID 2d934da3-bd77-4470-e063-6294a90a64f5
- US Food and Drug Administration. Certain prescription insomnia medicines: new boxed warning due to risk of serious injuries caused by sleepwalking, sleep driving and other activities while not fully awake. Safety alert, posted April 30, 2019